Abbonarsi

Streptococcus bovis endocarditis: Update from a multicenter registry - 16/12/15

Doi : 10.1016/j.ahj.2015.10.012 
Carmen Olmos, MD, PhD a, , Isidre Vilacosta, MD, PhD a, Cristina Sarriá, MD, PhD b, Javier López, MD, PhD c, Carlos Ferrera, MD a, Carmen Sáez, MD b, David Vivas, MD, PhD a, Miguel Hernández, MD b, Cristina Sánchez-Enrique, MD a, Pablo Elpidio García-Granja, MD c, Elisa Pérez-Cecilia, MD a, Luis Maroto, MD, PhD a, José Alberto San Román, MD, PhD c
a Instituto Cardiovascular, Hospital Clínico San Carlos, Madrid, Spain 
b Servicio de Medicina Interna-Infecciosas, Instituto de Investigación Sanitaria del Hospital Universitario de la Princesa, Madrid, Spain 
c Instituto de Ciencias del Corazón (ICICOR), Hospital Universitario de Valladolid, Valladolid, Spain 

Reprint requests: Carmen Olmos, MD, PhD, Instituto Cardiovascular, Hospital Clínico San Carlos, Prof Martín Lagos s/n, 28040 Madrid, Spain.Instituto Cardiovascular, Hospital Clínico San Carlos, Prof Martín Lagos s/nMadrid28040Spain

Riassunto

Background

Infective endocarditis (IE) due to Streptococcus bovis has been classically associated with elderly patients, frequently involving >1 valve, with large vegetations and high embolic risk, which make it a high-risk group. Our aim is to analyze the current clinical profile and prognosis of S bovis IE episodes, in comparison to those episodes caused by viridans group streptococci and enterococci.

Methods

We analyzed 1242 consecutive episodes of IE prospectively recruited on an ongoing multipurpose database, of which 294 were streptococcal left-sided IE and comprised our study group. They were classified into 3 groups: group I (n = 47), episodes of IE due to S bovis; group II (n = 134), episodes due to viridans group streptococci; and group III (n = 113), those episodes due to enterococci.

Results

The incidence of enterococci IE has significantly increased in the last 2 decades (6.4% [1996-2004] vs 11.1% [2005-2013]; P = .005), whereas the incidence of IE due to S bovis and viridans streptococci have remained stable (4% and 10%, respectively).

Gender distribution was similar in the 3 groups. Patients with S bovis and enterococci IE were older than those from group II. Nosocomial acquisition was more frequent in group III. Concerning comorbidity, diabetes mellitus (36.7% vs 9.2% vs 26.8%; P < .001) was more common in groups I and III. Chronic renal failure was more prevalent in patients from group III (4.2% vs 1.5% vs 19%; P < .001). Prosthetic valve IE was more frequent in enterococcal IE. Infection upon normal native valves was more frequent in S bovis IE. Colorectal tumors were found in 69% of patients from this group.

Vegetation detection was similar in the 3 groups. However, vegetation size was smaller in S bovis IE. During hospitalization, in-hospital complications and in-hospital mortality were higher in enterococci episodes.

Conclusions

S bovis IE accounts for 3.8% of all IE episodes in our cohort; it is associated with a high prevalence of colonic tumors, with predominance of benign lesions, and affects patients without preexisting valve disease. It is related to small vegetations and a low rate of in-hospital complications, including systemic embolisms. In-hospital mortality is similar to that of viridans group streptococci.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Financial support: None.
 Conflicts of interest: None.


© 2015  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 171 - N° 1

P. 7-13 - gennaio 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • A randomized study of the safety and efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after coronary artery bypass graft surgery
  • Raghu Kolluri, Anna L. Plessa, Mark C. Sanders, Nishith K. Singh, Charles Lucore
| Articolo seguente Articolo seguente
  • An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention
  • Rahman Shah, Kelly C. Rogers, Khalid Matin, Raza Askari, Sunil V. Rao

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.